Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer

Inclusion Criteria: * Signed informed consent (IC) * Age greater than or equal to 18 years * Histologically or cytologically confirmed metastatic or recurrent colorectal tumors with no previous treatment for advanced disease. * At least one measurable lesion according to the RECIST criteria which has not been irradiated (i.e. newly arising lesions in previously irradiated areas are accepted). Minimum indicator lesion size: \> 10 mm measured by spiral CT or \>20mm measured by conventional techniques * ECOG performance status 0-1 * Life expectancy \> 3 months * ECG is normal Exclusion Criteria: * Pregnant or lactating woman * Any prior oxaliplatin treatment, with the exception of adjuvant therapy given \> 12 months prior to the beginning of study therapy,and any prior 5-fluorouracil treatment, with the exception of adjuvant therapy given \> 6 months prior to the beginning of study therapy * Any prior endostatin treatment * known hypersensitivity to 5-fluorouracil,oxaliplatin,leucovorin * History of persistent neurosensory disorder including but not limited to peripheral neuropathy * known DPD deficiency * Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer * Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) within the last 6 months * Any of the following laboratory values: * Abnormal hematologic values (neutrophils \< 1.5 x 109/L, platelet count \< 100 x 109/L) * Urine protein: creatinine ratio \>/= 1.0, Impaired renal function with estimated creatinine clearance \< 30 ml/min * Serum bilirubin \> 1.5 x upper normal limit. ALT, AST \> 2.5 x upper normal limit (or \> 5 x upper normal limit in the case of liver metastases) * Alkaline phosphatase \> 2.5 x upper normal limit (or \> 5 x upper normal limit in the case of liver metastases or \> 10 x upper normal limit in the case of bone disease) * use of full-dose anticoagulants or thrombolytics * known CNS metastases * serious nonhealing wound, ulcer, or bone fracture * clinically significant bleeding diathesis or coagulopathy